N-(3-甲基丁基)-N-甲胺盐酸盐 | 2419-59-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-(3-甲基丁基)-N-甲胺盐酸盐
• 中文别名: N,3-二甲基-1-丁胺；N-甲基戊烷-1-氨基盐酸盐
• 英文名称: N,3-dimethylbutan-1-amine hydrochloride
• 英文别名: N,3-dimethylbutan-1-amine;hydrochloride
• CAS: 2419-59-2
• 化学式: C6H16ClN
• mdl: MFCD00101606
• 分子量: 137.65
• InChiKey: VCJIRVHWQPACGL-UHFFFAOYSA-N

物化性质

• 溶解度：
  可微溶于水

计算性质

• 辛醇/水分配系数(LogP)：
  1.42
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2921199090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

文献信息

• [EN] PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE PROTÉINE TYROSINE PHOSPHATASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：CALICO LIFE SCIENCES LLC

  公开号：WO2020186199A1

  公开（公告）日：2020-09-17

  Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN 1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

  本文提供了用于抑制蛋白酪氨酸磷酸酶的化合物、组合物和方法，例如蛋白酪氨酸磷酸酶非受体型2（PTPN2）和/或蛋白酪氨酸磷酸酶非受体型1（PTPN1），以及用于治疗对PTPN1或PTPN2抑制剂治疗有良好反应的相关疾病、紊乱和状况的方法，例如癌症或代谢性疾病。
• Pyrazinecarboxamide derivatives as CB1 antagonists
  申请人：Hebeisen Paul

  公开号：US20070293509A1

  公开（公告）日：2007-12-20

  The present invention relates to compounds of the formula I: wherein R 1 to R 8 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors, such as obesity.

  本发明涉及以下式I的化合物： 其中R1至R8如描述和索赔中定义，并且其药学上可接受的盐。这些化合物对于治疗和/或预防与调节CB1受体相关的疾病，如肥胖症，是有用的。
• 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors
  申请人：Baeschlin Daniel Kaspar

  公开号：US20080194629A1

  公开（公告）日：2008-08-14

  The invention relates to 3,5-piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-piperidine compound, and/or a method of treatment comprising administering a 3,5-piperidine compound, a method for the manufacture of a 3,5-piperidine compound, and novel intermediates and partial steps for their synthesis. Especially, the 3,5-piperidine compounds have the formula I, wherein the symbols have the meanings described in the specification.

  本发明涉及3,5-哌啶化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖肾素活性的疾病(=紊乱)；该类化合物用于制备用于治疗依赖肾素活性疾病的制药配方；该类化合物用于治疗依赖肾素活性的疾病；包括3,5-哌啶化合物的制药配方和/或包括给予3,5-哌啶化合物的治疗方法，一种制备3,5-哌啶化合物的方法，以及其合成的新中间体和部分步骤。特别地，3,5-哌啶化合物具有式I，其中符号具有规范中描述的含义。
• Protein tyrosine phosphatase inhibitors and methods of use thereof
  申请人：Calico Life Sciences LLC

  公开号：US10851073B2

  公开（公告）日：2020-12-01

  Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

  本文提供的化合物、组合物和方法可用于抑制蛋白酪氨酸磷酸酶，例如蛋白酪氨酸磷酸酶非受体2型（PTPN2）和/或蛋白酪氨酸磷酸酶非受体1型（PTPN1），以及治疗对PTPN1或PTPN2抑制剂治疗有良好反应的相关疾病、失调和病症，例如癌症或代谢性疾病。
• 2-PYRAZINECARBOXAMIDE DERIVATIVES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2035394A1

  公开（公告）日：2009-03-18